Genmab — September 2018
-
God morgen
-
God morgen
-
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. https://www.ncbi.nlm.nih.gov/pubmed/30080247 ... In conclusion, a high proportion of RRMM patients benefitted from retreatment with IMiDs and PIs after daratumumab treatment.
-
Bikube. Dejlig læsning. Link https://seekingalpha.com/article/4203703-darzalex-growing-faster-revlimid-particularly-outside-u-s
-
Our report provides the first indication that daratumumab and IMiDs could act synergistically by unique mechanisms, overcoming resistance to both classes, and their combinations could be the backbone of myeloma therapy across several different lines of therapy
-
De anonyme hælder stille og roligt ud...
-
Nordea på Børsen Play: "Hold dig væk denne uge hvis du ikke kan li`at få tæsk"
-
Og det er ikke specifikt møntet på Genmab men markedet som helhed...Trump spøger igen med nye toldsatser mod Kina.
-
Lidt fra Plesner om 1.line http://www.pmlive.com/pharma_news/darzalex_powers_ahead_with_frontline_myeloma_approval_in_europe_1251144
-
bibob...den ukuelige optimist fra Sæby
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind